Signal transducer and activator of transcription 4 in liver diseases

International Journal of Biological Sciences

Volumn 11, Issue 4, 2015, Pages 448-455

  Wang, Yan ^a   Qu, Aijuan ^c,c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Chronic hepatitis; Cytokines; Hepatocellular carcinoma; Liver fibrosis; Liver injury; STAT4

Indexed keywords

HEPATITIS C VIRUS;

STAT4 PROTEIN;

ANIMAL; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TUMOR; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; LIVER NEOPLASMS; SIGNAL TRANSDUCTION; STAT4 TRANSCRIPTION FACTOR;

EID: 84928796596     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.11164     Document Type: Review

References (89)

1. Gao B. Cytokines, STATs and liver disease. Cell Mol Immunol. 2005; 2: 92-100.
2. Frucht DM, Aringer M, Galon J, Danning C, Brown M, et al. Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation. J Immunol. 2000; 164: 4659-4664.
3. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol. 1998; 16: 293-322.
4. Nishikomori R, Usui T, Wu CY, Morinobu A, O'Shea JJ, et al. Activated STAT4 has an essential role in Th1 differentiation and proliferation that is independent of its role in the maintenance of IL-12R beta 2 chain expression and signaling. J Immunol. 2002; 169: 4388-4398.
5. Bacon CM, Petricoin EF, 3rd, Ortaldo JR, Rees RC, Larner AC, et al. Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. Proc Natl Acad Sci U S A. 1995; 92: 7307-7311.
6. Cho SS, Bacon CM, Sudarshan C, Rees RC, Finbloom D, et al. Activation of STAT4 by IL-12 and IFN-alpha: evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J Immunol. 1996; 157: 4781-4789.
7. Iida K, Suzuki K, Yokota M, Nakagomi D, Wakashin H, et al. STAT4 is required for IFN-beta-induced MCP-1 mRNA expression in murine mast cells. Int Arch Allergy Immunol. 2011; 155 Suppl 1: 71-76.
8. Miyagi T, Gil MP, Wang X, Louten J, Chu WM, et al. High basal STAT4 balanced by STAT1 induction to control type 1 interferon effects in natural killer cells. J Exp Med. 2007; 204: 2383-2396.
9. Wang KS, Ritz J, Frank DA. IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells. J Immunol. 1999; 162: 299-304.
10. Subramaniam SV, Cooper RS, Adunyah SE. Evidence for the involvement of JAK/STAT pathway in the signaling mechanism of interleukin-17. Biochem Biophys Res Commun. 1999; 262: 14-19.
11. Morinobu A, Gadina M, Strober W, Visconti R, Fornace A, et al. STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation. Proc Natl Acad Sci U S A. 2002; 99: 12281-12286.
12. Barnes J, Agarwal SK. Targeting STAT4 in systemic sclerosis: a promising new direction. Expert Rev Clin Immunol. 2011; 7: 445-448.
13. Wang C, Sandling JK, Hagberg N, Berggren O, Sigurdsson S, et al. Genome-wide profiling of target genes for the systemic lupus erythematosus-associated transcription factors IRF5 and STAT4. Ann Rheum Dis. 2012.
14. Piotrowski P, Lianeri M, Wudarski M, Olesinska M, Jagodzinski PP. Contribution of STAT4 gene single-nucleotide polymorphism to systemic lupus erythematosus in the Polish population. Mol Biol Rep. 2012; 39: 8861-8866.
15. Liang YL, Wu H, Shen X, Li PQ, Yang XQ, et al. Association of STAT4 rs7574865 polymorphism with autoimmune diseases: a meta-analysis. Mol Biol Rep. 2012; 39: 8873-8882.
16. Mohamed RH, Pasha HF, El-Shahawy EE. Influence of TRAF1/C5 and STAT4 genes polymorphisms on susceptibility and severity of rheumatoid arthritis in Egyptian population. Cell Immunol. 2012; 273: 67-72.
17. Kim SW, Kim ES, Moon CM, Kim TI, Kim WH, et al. Abnormal Genetic and Epigenetic Changes in Signal Transducer and Activator of Transcription 4 in the Pathogenesis of Inflammatory Bowel Diseases. Dig Dis Sci. 2012.
18. Lee HS, Park H, Yang S, Kim D, Park Y. STAT4 polymorphism is associated with early-onset type 1 diabetes, but not with late-onset type 1 diabetes. Ann N Y Acad Sci. 2008; 1150: 93-98.
19. Martinez A, Varade J, Marquez A, Cenit MC, Espino L, et al. Association of the STAT4 gene with increased susceptibility for some immune-mediated diseases. Arthritis Rheum. 2008; 58: 2598-2602.
20. Lupov IP, Voiles L, Han L, Schwartz A, De La Rosa M, et al. Acquired STAT4 deficiency as a consequence of cancer chemotherapy. Blood. 2011; 118: 6097-6106.
21. Wurster AL, Tanaka T, Grusby MJ. The biology of Stat4 and Stat6. Oncogene. 2000; 19: 2577-2584.
22. Visconti R, Gadina M, Chiariello M, Chen EH, Stancato LF, et al. Importance of the MKK6/p38 pathway for interleukin-12-induced STAT4 serine phosphorylation and transcriptional activity. Blood. 2000; 96: 1844-1852.
23. Chang CP, Yang MC, Lei HY. Concanavalin A/IFN-gamma triggers autophagy-related necrotic hepatocyte death through IRGM1-mediated lysosomal membrane disruption. PLoS One. 2011; 6: e28323.
24. Good SR, Thieu VT, Mathur AN, Yu Q, Stritesky GL, et al. Temporal induction pattern of STAT4 target genes defines potential for Th1 lineage-specific programming. J Immunol. 2009; 183: 3839-3847.
25. Nakahira M, Ahn HJ, Park WR, Gao P, Tomura M, et al. Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J Immunol. 2002; 168: 1146-1153.
26. Ouyang W, Jacobson NG, Bhattacharya D, Gorham JD, Fenoglio D, et al. The Ets transcription factor ERM is Th1-specific and induced by IL-12 through a Stat4-dependent pathway. Proc Natl Acad Sci U S A. 1999; 96: 3888-3893.
27. Galon J, Sudarshan C, Ito S, Finbloom D, O'Shea JJ. IL-12 induces IFN regulating factor-1 (IRF-1) gene expression in human NK and T cells. J Immunol. 1999; 162: 7256-7262.
28. Lv L, Zhang J, Huang X, Zhao Y, Zhou Z, et al. Lentivirus-mediated RNA interference targeting STAT4 inhibits the proliferation of vascular smooth muscle cells. Arch Med Res. 2008; 39: 582-589.
29. Grant LR, Yao ZJ, Hedrich CM, Wang F, Moorthy A, et al. Stat4-dependent, T-bet-independent regulation of IL-10 in NK cells. Genes Immun. 2008; 9: 316-327.
30. Visekruna A, Volkov A, Steinhoff U. A key role for NF-kappaB transcription factor c-Rel in T-lymphocyte-differentiation and effector functions. Clin Dev Immunol. 2012; 2012: 239368.
31. Yuzhalin AE, Kutikhin AG. Interleukin-12: clinical usage and molecular markers of cancer susceptibility. Growth Factors. 2012; 30: 176-191.
32. Sinigaglia F, D'Ambrosio D, Panina-Bordignon P, Rogge L. Regulation of the IL-12/IL-12R axis: a critical step in T-helper cell differentiation and effector function. Immunol Rev. 1999; 170: 65-72.
33. Subleski JJ, Hall VL, Back TC, Ortaldo JR, Wiltrout RH. Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver. Cancer Res. 2006; 66: 11005-11012.
34. Kaplan MH, Sun YL, Hoey T, Grusby MJ. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature. 1996; 382: 174-177.
35. Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature. 1996; 382: 171-174.
36. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol. 1998; 70: 83-243.
37. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3: 133-146.
38. Rodriguez-Galan MC, Reynolds D, Correa SG, Iribarren P, Watanabe M, et al. Coexpression of IL-18 strongly attenuates IL-12-induced systemic toxicity through a rapid induction of IL-10 without affecting its antitumor capacity. J Immunol. 2009; 183: 740-748.
39. Huang Y, Lei Y, Zhang H, Zhang M, Dayton A. Interleukin-12 treatment down-regulates STAT4 and induces apoptosis with increasing ROS production in human natural killer cells. J Leukoc Biol. 2011; 90: 87-97.
40. Yoshida K, Yang GX, Zhang W, Tsuda M, Tsuneyama K, et al. Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. Hepatology. 2009; 50: 1494-1500.
41. Zhu R, Diem S, Araujo LM, Aumeunier A, Denizeau J, et al. The Pro-Th1 cytokine IL-12 enhances IL-4 production by invariant NKT cells: relevance for T cell-mediated hepatitis. J Immunol. 2007; 178: 5435-5442.
42. Nicoletti F, Di Marco R, Zaccone P, Salvaggio A, Magro G, et al. Murine concanavalin A-induced hepatitis is prevented by interleukin 12 (IL-12) antibody and exacerbated by exogenous IL-12 through an interferon-gamma-dependent mechanism. Hepatology. 2000; 32: 728-733.
43. Wang Y, Feng D, Wang H, Xu MJ, Park O, et al. STAT4 Knockout Mice Are More Susceptible to Concanavalin A-Induced T-Cell Hepatitis. Am J Pathol. 2014; 184: 1785-1794.
44. Cavanaugh VJ, Guidotti LG, Chisari FV. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol. 1997; 71: 3236-3243.
45. Otano I, Suarez L, Dotor J, Gonzalez-Aparicio M, Crettaz J, et al. Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B. Hepatology. 2012; 56: 474-483.
46. Umemura T, Joshita S, Yoneda S, Katsuyama Y, Ichijo T, et al. Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C. Antivir Ther. 2011; 16: 1073-1080.
47. Trinchieri G. Type I interferon: friend or foe? J Exp Med. 2010; 207: 2053-2063.
48. Ronnblom L. The type I interferon system in the etiopathogenesis of autoimmune diseases. Ups J Med Sci. 2011; 116: 227-237.
49. Shen XD, Ke B, Ji H, Gao F, Freitas MC, et al. Disruption of Type-I IFN pathway ameliorates preservation damage in mouse orthotopic liver transplantation via HO-1 dependent mechanism. Am J Transplant. 2012; 12: 1730-1739.
50. Hong F, Jaruga B, Kim WH, Radaeva S, El-Assal ON, et al. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J Clin Invest. 2002; 110: 1503-1513.
51. Kato A, Graul-Layman A, Edwards MJ, Lentsch AB. Promotion of hepatic ischemia/reperfusion injury by IL-12 is independent of STAT4. Transplantation. 2002; 73: 1142-1145.
52. Shen XD, Ke B, Zhai Y, Gao F, Anselmo D, et al. Stat4 and Stat6 signaling in hepatic ischemia/reperfusion injury in mice: HO-1 dependence of Stat4 disruption-mediated cytoprotection. Hepatology. 2003; 37: 296-303.
53. Li N, Liu YH, Li SL, Fu CY, Zhou RR, et al. Protective role of synthetic oligodeoxynucleotides expressing immunosuppressive TTAGGG motifs in concanavalin A-induced hepatitis. Immunol Lett. 2013; 151: 54-60.
54. Wang C, Zhang X, Zhu B, Hu D, Wu J, et al. Relationships between tumour necrosis factor-alpha, interleukin-12B and interleukin-10 gene polymorphisms and hepatitis B in Chinese Han haemodialysis patients. Nephrology (Carlton). 2012; 17: 167-174.
55. Edlich B, Ahlenstiel G, Zabaleta Azpiroz A, Stoltzfus J, Noureddin M, et al. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology. 2012; 55: 39-48.
56. Byrnes AA, Li DY, Park K, Thompson D, Mocilnikar C, et al. Modulation of the IL-12/IFN-gamma axis by IFN-alpha therapy for hepatitis C. J Leukoc Biol. 2007; 81: 825-834.
57. Miyagi T, Takehara T, Nishio K, Shimizu S, Kohga K, et al. Altered interferon-alpha-signaling in natural killer cells from patients with chronic hepatitis C virus infection. J Hepatol. 2010; 53: 424-430.
58. Liao Y, Cai B, Li Y, Chen J, Ying B, et al. Association of HLA-DP/DQ, STAT4 and IL-28B variants with HBV viral clearance in Tibetans and Uygurs in China. Liver Int. 2014.
59. Urban TJ, Shen Y, Stolz A, Chalasani N, Fontana RJ, et al. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics. 2012; 22: 784-795.
60. Urban TJ, Goldstein DB, Watkins PB. Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here? Pharmacogenomics. 2012; 13: 735-738.
61. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005; 115: 209-218.
62. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008; 134: 1655-1669.
63. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008; 88: 125-172.
64. Kong X, Feng D, Wang H, Hong F, Bertola A, et al. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology. 2012; 56: 1150-1159.
65. Kong X, Horiguchi N, Mori M, Gao B. Cytokines and STATs in Liver Fibrosis. Front Physiol. 2012; 3: 69.
66. Wang H, Lafdil F, Kong X, Gao B. Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci. 2011; 7: 536-550.
67. Avouac J, Furnrohr BG, Tomcik M, Palumbo K, Zerr P, et al. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum. 2011; 63: 800-809.
68. Cheng YL, Song WJ, Liu WQ, Lei JH, Kong Z, et al. The effects of interleukin (IL)-12 and IL-4 deficiency on worm development and granuloma formation in Schistosoma japonicum-infected mice. Parasitol Res. 2012; 110: 287-293.
69. Hirschfield GM, Invernizzi P. Progress in the genetics of primary biliary cirrhosis. Semin Liver Dis. 2011; 31: 147-156.
70. Eurich D, Boas-Knoop S, Struecker B, Neuhaus R, Neuhaus P, et al. Genetic variants of STAT-4 affect the development of graft fibrosis after liver transplantation for HCV-induced liver disease. Transplantation. 2013; 95: 203-208.
71. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol. 1995; 13: 251-276.
72. Uemura A, Takehara T, Miyagi T, Suzuki T, Tatsumi T, et al. Natural killer cell is a major producer of interferon gamma that is critical for the IL-12-induced anti-tumor effect in mice. Cancer Immunol Immunother. 2010; 59: 453-463.
73. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993; 178: 1223-1230.
74. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol. 1994; 153: 1697-1706.
75. Zou JP, Yamamoto N, Fujii T, Takenaka H, Kobayashi M, et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol. 1995; 7: 1135-1145.
76. Mu J, Zou JP, Yamamoto N, Tsutsui T, Tai XG, et al. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res. 1995; 55: 4404-4408.
77. Harada N, Shimada M, Okano S, Suehiro T, Soejima Y, et al. IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice. J Immunol. 2004; 173: 6635-6644.
78. Liu L, Xu Y, Liu Z, Chen J, Zhang Y, et al. IL12 polymorphisms, HBV infection and risk of hepatocellular carcinoma in a high-risk Chinese population. Int J Cancer. 2011; 128: 1692-1696.
79. Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, et al. Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother Emphasis Tumor Immunol. 1995; 17: 71-77.
80. Hess SD, Egilmez NK, Bailey N, Anderson TM, Mathiowitz E, et al. Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma. J Immunol. 2003; 170: 400-412.
81. Kozar K, Kaminski R, Switaj T, Oldak T, Machaj E, et al. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice. Clin Cancer Res. 2003; 9: 3124-3133.
82. Smyth MJ, Taniguchi M, Street SE. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol. 2000; 165: 2665-2670.
83. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood. 1996; 87: 3877-3882.
84. Chang CJ, Chen YH, Huang KW, Cheng HW, Chan SF, et al. Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors. Hepatology. 2007; 45: 746-754.
85. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol. 2005; 6: 722-729.
86. Swann JB, Hayakawa Y, Zerafa N, Sheehan KC, Scott B, et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol. 2007; 178: 7540-7549.
87. Wang L, Jia D, Duan F, Sun Z, Liu X, et al. Combined anti-tumor effects of IFN-alpha and sorafenib on hepatocellular carcinoma in vitro and in vivo. Biochem Biophys Res Commun. 2012; 422: 687-692.
88. Robertson MJ, Chang HC, Pelloso D, Kaplan MH. Impaired interferon-gamma production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma. Blood. 2005; 106: 963-970.
89. Jiang DK, Sun J, Cao G, Liu Y, Lin D, et al. Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet. 2013; 45: 72-75.